What question did this study set out to answer?

This research aims to identify biomarkers DKK1 and S100P for pancreatic ductal adenocarcinoma (PDAC) progression and their implications in prognosis.

August 2, 2026Translational OncologyOpen Access

Unraveling the roles of DKK1 and S100P in pancreatic ductal adenocarcinoma: Insights from machine learning, single-cell/spatial transcriptomics, and functional validation

View Full Paper

Ask AI

Bookmark

This research aims to identify biomarkers DKK1 and S100P for pancreatic ductal adenocarcinoma (PDAC) progression and their implications in prognosis.
Integrated bulk transcriptomic datasets, single-cell RNA sequencing, and spatial transcriptomics for analysis.
Used LASSO and SVM-RFE algorithms to identify candidate genes, particularly DKK1 and S100P.
Conducted functional validation experiments to assess the impact of knocking down DKK1 and S100P on PDAC cell proliferation and migration.
DKK1 and S100P exhibited stronger diagnostic performance than NMU and IGFBP3.
Survival analyses confirmed DKK1 as a robust prognostic marker; S100P indicated partial prognostic relevance.
Knockdown of DKK1 or S100P significantly inhibited PDAC cell proliferation and migration, indicating their functional role.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates DKK1 and S100P as biomarkers in pancreatic ductal adenocarcinoma, indicating their potential clinical relevance.

Mao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial investigates DKK1 and S100P as biomarkers in pancreatic ductal adenocarcinoma, indicating their potential clinical relevance.